SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990; 66: 1039-1044.
  • 2
    Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1488-1490.
  • 3
    Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
  • 4
    Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26: 242-245.
  • 5
    Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003; 98: 2592-2598.
  • 6
    Dawson NA, Halabi S, Ou SS, et al. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of Cancer and Leukemia Group B trial 90004. Clin Genitourin Cancer. 2008; 6: 110-116.
  • 7
    Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinology. 1997; 18: 1-22.
  • 8
    Ferrara N. Role of vascular endothelial growth factor in regulation of angiogenesis. Kidney Int. 1999; 56: 794-814.
  • 9
    Pallares J, Rojo F, Iriarte J, et al. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol. 2006; 21: 857-865.
  • 10
    Ferrer FA, Miller LJ, Andrawis RJ. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of FEGG by human prostate cancer cells. J Urol. 1997; 157: 2329-2333.
  • 11
    Duque J, Loughlin K, Adam R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999; 45: 523-527.
  • 12
    Bok R, Halabi S, Fei D, et al. VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: a CALGB study. Cancer Res. 2001; 61: 2533-2536.
  • 13
    George D, Halabi S, Shepard T, et al. Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone refractory prostate cancer: a CALGB study. Clin Cancer Res. 2001; 7: 1932-1936.
  • 14
    Reese D, Fratesi P, Corry M. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhu-MAb VEGF) for the treatment of androgen-independent prostate cancer. Prostate. 2001; 3: 65-70.
  • 15
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461-3467.
  • 16
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 17
    Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001; 19: 2509-2516.
  • 18
    Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
  • 19
    Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 1232-1239.
  • 20
    Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma. Cancer. 2004; 101: 2755-2759.